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Background: Reducing ischemic damage is one of the goals of surgery. The aim of this study was to apply
human VEGF-A and FGF-2 DNA-mediated gene therapy in order to identify their effects in the healing of
ischemic colon anastomoses and eliminating the negative effects of ischemia.
Methods: Forty male Wistar albino rats weighing 250e280 g were divided into ﬁve equal groups (n ¼ 8)
as follows: group 1: control, ischemic left colonic anastomosis; group; 2: ischemic left colonic anasto-
mosis with control plasmid delivery; group 3: ischemic left colonic anastomosis with VEGF plasmid
delivery; group 4: ischemic left colonic anastomosis with FGF plasmid delivery; group 5: ischemic left
colonic anastomosis with VEGF and FGF plasmid delivery. All rats were sacriﬁced on the 4th post-
operative day. Anastomosis burst pressures were measured for mechanical examination of anastomosis.
Tissue hydroxyprolin, VEGF and FGF levels were determined as biochemical parameters. Necrosis, epi-
thelisation, inﬂammatory processes, ﬁbroblastic activity, collagen deposition and neovascularisation at
the anastomic site were studied.
Results: VEGF, FGF and combined therapy signiﬁcantly accelerated many of the histological parameters of
healing, including ﬁbroblast activation, collagen deposition, and angiogenesis, and augmented the levels
of hydroxyproline and bursting pressure.
Conclusions: This is the ﬁrst study to use gene therapy with growth factors for the healing of ischemic
colonic anastomosis. This therapy can be effectively used in increasing ischemic anastomosis wound
healing.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Ischemia is one of the most important contributing causes of
dehiscence of intestinal anastomoses. After gastrointestinal
surgery, many instances of leakage during clinical situations exhibit
hypoperfusion of anastomoses. If the degree of hypoxia is enough
to interfere with tissue viability, tissues can necrose and lead to
delayed wound healing. Preventing or reducing the ischemic
damage is one of the goals of surgery.1,2ital Department of Surgery,
7777.
pe).
ciates Ltd. Published by Elsevier LtGrowth factors (GF) are the engines or modulating factors that
drive wound healing. Through their induction of chemotaxis and
cell proliferation and by stimulating cells to upregulate protein
production, they determine extracellular matrix synthesis, matrix
turnover, and cell death.3,4 In the gastrointestinal system, the repair
process is initiated after anastomoses by the release of various
growth factors.5 The ﬁbroblast growth factor (FGF) family has
a broad mitogenic spectrum, and members of this family stimulate
proliferation of various cells of mesodermal, ectodermal, and
endodermal origin.5 Vascular endothelial growth factor (VEGF),
especially VEGF-A, has been identiﬁed as a major regulator of
vasculogenesis and angiogenesis during development, indicating
that it may also be involved in the regulation of angiogenesis during
wound healing.6d. All rights reserved.
Fig. 1. VEGF-A plasmid construct.
Fig. 2. FGF-2 plasmid construct.
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the process of manipulating genes and involves the insertion of
a desired gene (the transgene) into the recipient’s cells.7 Plasmids
are molecules of DNA that are found in bacteria but are distinct
from the bacterial chromosome. Plasmid DNA has a number of
advantages over viral vectors as a vector for non-viral gene
therapy.8 The direct injection of naked plasmid DNA into the target
tissue enables transgene expression.9 The simplicity of injecting
naked plasmid DNA into tissuewith a syringe is an attractiveway to
conduct gene therapy research. The addition of growth factors into
the target tissue in order to enhance wound healing is a new
approach. In this study, human VEGF-A and bFGF-2 genes were
separately incorporated into two recombinant plasmids in order to
identify their effects on the healing of ischemic colon anastomosis
and eliminate the negative effects of ischemia.
2. Materials and methods
This study was completed in the Department of Genetics at The Institute of
Experimental Medicine, Istanbul University. The study protocol was approved by the
Institutional Animal Care and Use Committee at Istanbul University. Forty male
Wistar albino rats weighing 250e280 g were divided into ﬁve equal groups (n ¼ 8).
The animals were housed at 21 C and were given tap water and standard rat food.
Group 1: (Control) Ischemic left colonic anastomosis
Group 2: (Control) Ischemic left colonic anastomosis þ plasmid delivery
Group 3: Ischemic left colonic anastomosis þ VEGF-A plasmid delivery
Group 4: Ischemic left colonic anastomosis þ FGF plasmid delivery
Group 5: Ischemic left colonic anastomosis þ VEGF-A and FGF plasmid delivery
All of the rats were sacriﬁced on postoperative day 4. Anastomosis burst pres-
sures were measured for mechanical examination of anastomosis. Tissue hydrox-
yproline, VEGF and FGF levels were examined for biochemical parameters. Necrosis,
epithelisation, inﬂammatory processes, ﬁbroblastic activity, collagen deposition and
neovascularisation at the anastomic site were studied using a light microscope.
2.1. Surgical procedure
After one night of fasting, the animals were anaesthetised by an intramuscular
injection of ketamine hydrochloride (50e100mg per kg of body weight). Abdominal
access was achieved through a midline incision 4 cm long, and the left colon was
diverted 3 cm proximal to the peritoneal reﬂection. In order to establish ischemic
colon anastomosis, vessels in the mesocolon between 2 cm proximal and 2 cm distal
to the anastomosis line were ligated. After the faecal contents had been removed,
a standardised end-to-end anastomosis was made from eight interrupted, inverted
sutures of 6/0 polypropylene. After the surgical procedure, group 2 received local
injection of 2 mg plasmid in 0.5 mL 0.9% NaCl into the tissues surrounding the
anastomotic area. Groups 3 and 4 were given VEGF-A plasmid or FGF plasmid with
physiological serum (0.5 ml 0.9% NaCl, 1 mg VEGF-A, 1 mg FGF) and the last group
(group 5) was given VEGF-A and FGF plasmid (0.5ml 0.9% NaClþ 1 mg VEGF-Aþ 1 mg
FGF), all locally into the tissues surrounding the anastomotosis. Once surgical
bleeding was under control, 2 cc of 0.9% NaCl was injected intraperitoneally and the
abdomen was closed with 3/0 continuous silk sutures. Water was given after 12 h
and food was given 24 h after the surgery.
2.2. Plasmid constructions and injections
VEGF-A and FGF-2 expression plasmids were constructed separately by ligating
full-length human VEGF-A (Gene ID: 7422) and FGF-2 (Gene ID: RR) cDNAs into
pcDNA4 (Invitrogen). Brieﬂy, total RNA was isolated from cultured cells using the
total RNA puriﬁcation kit according to the manufacturer’s recommendations (Qia-
gen). After reverse transcription, PCR was ampliﬁed with the VEGF-A forward oligo
50-GAATTCGCCGACATGACGGACAGACAGACAGACACCGCC-30 containing an EcoRI site
and the reverse oligo 50TCTAGATCACCGCCTCGGCTTGTCACATCTGC-30 with a modi-
ﬁed XbaI site at the 50 and 30 ends. The FGF-2 forward 50- GAATTCGCCA-
CATGGTGGGTGTGGGGGGTGGAGATGTAGA-30 oligo containing EcoRI and the
reverse oligo 50-TCTAGATCAGCTCTTAGCAGACATTGGAAGA-30 with an XbaI site were
created. The puriﬁed PCR fragments and pcDNA4 were double digested with EcoRI
and XbaI restriction enzymes. The digested fragments were recovered from a 1% low
melting agarose gel and DNA was eluted from the sliced agarose gel using a gel
extraction kit (Qiagen). Fifty nanogrammes of EcoRI- and XbaI-digested and
dephosphorylated vector DNA and 1 ml of PCR product were incubated with DNA
ligase buffer containing T4 DNA ligase at 16 C overnight. Three microlitres of
ligation reaction and 100 ml of DH5 alpha competent E. coli were heat-shock
transformed at 42 C and spread on agar plates containing 100 mg/ml ampicillin.Plates were incubated overnight at 37 C. PCR-tested and selected positive clones
were conﬁrmed by sequencing (Refgen Co, Turkey). Plasmids were puriﬁed using an
Endofree maxi Plasmid kit (Qiagen Co). A ratio of 1:1 the of two plasmid constructs,
each with either human VEGF-A (1 mg) (Fig. 1) or FGF-2 (1 mg) (Fig. 2) DNA were
mixed and administered onto the local anastomosis of the rat colon. In addition, an
empty pcDNA4 plasmid (2 mg) was used as a control.
2.3. Measurement of colonic bursting pressure
The abdominal incision was reopened and the anastomotic sutures lines were
identiﬁed. The anastomotic segment was found and bursting pressure was
measured in situ without detaching adhesions. The bursting pressure of the anas-
tomotic segment was measured with a mercury manometer and a constant ﬂow
pump. Brieﬂy, a 16-gauge silastic catheter was inserted via the anal canal. The
proximal section of the anastomosis was ligated with 2/0 silk and continuously
infused through the catheter via a tube pump at a rate of 4ml/min. Bursting pressure
was recorded (mmHg) as the peak pressure attained before rupture of the anasto-
mosis, which resulted in an abrupt drop in pressure.
Table 1
Bursting pressures and hydroxyproline contents in all groups. p value comparison between group 1 (control) and groups 2e5. All values expressed as mean  SD.
Bursting Pressure (mmHg)
Group 1
(control)
Group 2
(empty plasmid delivery)
Group 3
(VEGF-A plasmid)
Group 4
(FGF plasmid)
Group 5
(VEGF-A þ FGF plasmids)
Mean  SD 59.4  20 91.3  22 106.3  21 103.8  22 126.3  27
p p < 0.05 p < 0.01 p < 0.01 p < 0.01
Hydroxyproline content (mg/mg)
Mean  SD 0.42  0.07 0.43  0.08 0.51  0.09 0.8  0.05 1.5  0.04
p p > 0.05 p < 0.05 p < 0.01 p < 0.01
*SD: Standard deviation.
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The tissue samples were excised 0.5 cm proximal and 0.5 cm distal to the
anastomosis line. All of the samples were then weighed and homogenised in
physiological serum as 20% homogenates using a Potter type glass homogeniser
(Heidolphy-RZR 2021, Germany). The homogenates were centrifuged at 1500 g for
15 min and the obtained supernatants were hydrolysed by adding equal amounts of
hydrochloric acid for 10e18 h. Using a hydroxyproline kit (Hipronisticon, Organon,
Holland) that is based on the principles of Stegeman and Stadler, the hydroxyproline
amount was calculated in micrograms per milligram of wet tissue by reading the
absorbance of the solution on a spectrometer at 560 nm. Total VEGF and FGF levels
were measured using VEGF and FGF ELISA kits (R&D Systems, USA). The measure-
ments were conducted according to the methods recommended by the manufac-
turer. Theminimum detection limit for total VEGFwas 31 pg/ml and the limit for FGF
was 1.0 pg/ml. All of the measurements were calculated while blinded to the group
identity.
2.5. Histopathological examinations
To determine histological and immunohistochemical assessments, the bursting
colon was excised, cleared of surrounding mesentery and fat, and washed with
saline. The anastomosis was excised together with 1 cm of the adjacent proximal
and distal colon. The tissues were ﬁxed in 10% formalin for approximately 24 h and
then embedded in parafﬁn. Transverse sections of the embedded tissue that were
3 mm in thickness were stained with haematoxylin and eosin, and histological
assessment was carried out by an experienced pathologist who was blinded to the
identity of the groups. Necrosis, epithelisation, inﬂammatory processes, ﬁbroblastic
activity, and neovascularisation at the anastomic site were studied and scored (from
0 to 3, where 0 is none, 1 is slight, 2 is moderate and 3 is dense). Masson’s trichrome
staining was used to distinguish cells from the surrounding connective tissue. Three
dyes were employed and solution C was used to stain collagen. Collagen deposition
was scored according to the density of the colonic tissue (from 0 to 3, using the
aforementioned scale).
Statistical analysis. Data are reported as mean  SD. All statistical analyses were
performed using SPSS 16.0 for Windows. The ManneWhitney U test was used to
compare continuous data between groups. Categorical variables are presented as
counts and percentages, and the KruskaleWallis and paired t-tests were used to
assess associations between discrete and group variables. A probability value of
P < 0.05 was considered to denote statistical signiﬁcance.
3. Results
3.1. Bursting pressure
The mean bursting pressure of ischemic colonic anastomoses in
group 5 was the highest of all of the groups (126 mmHg) (Table 1).Table 2
Tissue VEGF and FGF level in all groups. p value comparison between group 1 (control) a
Tissue VEGF-A and FGF level (pg/ml)
Group 1
(control)
Group 2
(empty plasmid delivery)
Mean  SD 200.5  15 258.6  39
p p > 0.05
Tissue FGF Level (pg/ml)
Mean  SD 0.91  0.16 1.03  0.22
p p > 0.05
*SD: Standard deviation.The bursting pressures in experimental groups 3e5 were signiﬁ-
cantly different from those in the group 2(p < 0.05, p < 0.01)
(Table 1).
3.2. Hydroxyproline content
We found signiﬁcantly higher hydroxyproline levels in groups
3e5 compared to the control group. Hydroxyproline levels were
increased in groups that had received growth factor therapy.
Hydroxyproline values for all groups are given in Table 1.
3.3. VEGF and FGF determination
We found signiﬁcantly higher VEGF levels in the tissue of groups
3 and 5 compared to the control group (p < 0.01) (Table 2). The FGF
levels were also higher in groups 3e5 compared to group 1
(p < 0.01) (Table 2).
3.4. Histological features
Therewas nomortality in any of the groups.We investigated the
early period of wound healing. We found higher levels of many
histological parameters such as collagen deposition, ﬁbroblast
activity and angiogenesis in groups 3 and 5 compared to the control
group 1 (Table 3, Fig. 3). In addition, we also found lower levels of
necrosis in groups 3, 4 and 5. There were no signiﬁcantly differ-
ences in histological parameters, such as epithelisation and
inﬂammation, between any of the groups (p > 0.05).
4. Discussion
Necrosis following hypoxia is one of the most important causes
of anastomotic leakage. Despite improvements in surgical and
medical techniques, the rates of anastomotic leakage remain high;
this necessitates the investigation of new agents and newmethods.
The success of the wound healing process depends on growth
factors, cytokines, and chemokines in a complex integration of
signals that coordinate cellular processes. These agents are bio-
logically active polypeptides that act to alter the growth,nd groups 2e5. All values expressed as mean  SD.
Group 3
(VEGF-A plasmid)
Group 4
(FGF plasmid)
Group 5
(VEGF-A þ FGF plasmids)
435  18 280  52 431  14
p < 0.01 p > 0.05 p < 0.01
1.58  0.2 2.57  0.19 2.73  0.15
p < 0.01 p < 0.01 p < 0.01
Table 3
Histological features that characterise the healing of ischemic anastomosis. All of the
parameters were scored from 0 to 3. p value comparison between group 1 and
groups 2e5.
Group 1 Group 2 Group3 Group 4 Group 5
Necrosis 2.8 2.4 1.5 1.6 1.2
p p > 0.05 p < 0.05 p < 0.05 p < 0.01
Epithelialisation 1.4 1.3 1.4 1.9 2
p p > 0.05 p > 0.05 p > 0.05 p > 0.05
Collagen deposition 1.1 1.8 2 2.4 2.3
p p > 0.05 p > 0.05 p < 0.01 p < 0.01
Fibroblast Activity 1 2 2.5 2.8 2.8
p p < 0.01 p < 0.01 p < 0.01 p < 0.01
Inﬂammation 2.4 2.9 2.6 2.8 2.5
p p > 0.05 p > 0.05 p > 0.05 p > 0.05
Angiogenesis 1.3 1.6 2.5 2.6 2.6
p p > 0.05 p < 0.01 p < 0.01 p < 0.01
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that play essential roles in wound healing, such as platelet-derived
growth factor (PDGF), epidermal growth factor (EGF), ﬁbroblast
growth factor (FGF), and vascular endothelial growth factor (VEGF),
can be referred to as connective tissue growth factors given their
local function and rare systemic effects.11,12 Little is known about
the ratio of growth factor concentrations in tissue, which may be as
important as the absolute concentration of individual growth
factors.3 Gene therapy in wound healing holds signiﬁcant promise
as a tool for understanding the role of growth factors in wound
healing and as a therapeutic strategy.13 There have been no studies
in the literature that address the delivery of growth factors via
plasmids for enhancement of ischemic wound healing. This study
demonstrated that FGF and VEGF-A gene transfer can be used safely
and successfully by local injection in ischemic colonic anastomoses.
Moreover, the study showed that this therapy signiﬁcantly accel-
eratedmany parameters of the healing process for ischemic colonic
anastomoses. Although there is a large body of work in theFig. 3. A: Dense collagen deposition (black arrow) is shown in the anastomotic area. The blu
vessels are seen (HE  100) (Group 3). C- Slight inﬂammation and angiogenesis are seen (HExliterature demonstrating the effects of growth factors in animals,
translation of these data into clinical practice has had limited
success.3
Assessment of anastomic healing mainly depends on mechan-
ical parameters, and measurement of bursting pressure is particu-
larly informative.14,15 Bursting pressures have been shown to
remain low for the ﬁrst 3e4 days after surgery.16,17 Bursting pres-
sure is the most commonly used method to assess anastomic
healing.18 The lowest level of bursting pressure (59 mmHg) was
found in group 1 (control). The bursting pressure was approxi-
mately 2 times greater in group 5 (126 mmHg) than in the control,
where this difference was statistically signiﬁcant (p < 0.01)
(Table 1). The higher bursting pressure measurements in the VEGF-
treated animals corresponds with studies that have shown the
opposite trend in animals treated with anti-angiogenic agents.19
Hydroxyproline levels, which indicate collagen content, were
determined. Hydroxyproline is found almost exclusively in collagen
and serves as a marker of the quantity of collagen in tissue.20 In this
study, bursting pressure and hydroxyproline levels showed that
therapy with growth factors augmented the healing process in
ischemic colonic anastomoses in groups 3, 4 and 5 (Table 1).
Numerous growth factors are produced during the healing
process. These growth factors stimulate continued wound cellular
proliferation, angiogenesis, and production of extracellular matrix
proteins and glycoproteins.18 With the assistance of platelet-
released VEGF and FGF, endothelial cells proliferate and angiogen-
esis ensues. This process is essential for the synthesis, deposition
and organisation of new extracellular matrix.10 FGF levels are
increased in the acute wound and play a role in the formation of
granulated tissue, re-epithelisation, and tissue remodelling.10
A characteristic feature of FGF is its interaction with heparan
sulphate proteoglycans, which stabilises FGF from thermal dena-
turation and proteolysis.21,22 The VEGF family, especially VEGF-A,
has been identiﬁed as a major regulator of vasculogenesis and
angiogenesis during development, indicating that it might also bee area is connective tissue (Masson Trichrome  40) (Group 4). B-Many newly-formed
40) (Group 1). d- Dense inﬂammation and angiogenesis can be seen (HEx40) (Group 5).
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Blood vessels respond to higher VEGF levels with vasodilation and
increased permeability and neovascularisation begins to take place
in its presence.4 In order to determine the efﬁciency of growth factor
delivery, we studied VEGF and FGF tissue levels in all groups. We
found signiﬁcantly higher VEGF levels in groups 3 and 5 than in the
control group. FGF level was increased in groups 3e5, which was
unexpected in the case of group 3 (VEGF plasmid). A potential
explanation of this result may be that FGF stimulates endothelial
cells, which then upregulate VEGF.10
When comparing the histological parameters, necrosis, angio-
genesis and ﬁbroblastic activity were similar to the previously
mentioned results. This study showed that delivery of growth
factors increased collagen production and angiogenesis and
decreased necrosis in groups 3e5. The necrosis score was highest
(2.8) in the control group (group 1), whereas the lowest score was
found in group 5 (1.2). This experimental groupwas associatedwith
newly-formed capillary networks. In addition, when comparing
rates of angiogenesis, rates were higher in groups 3e5, where these
increases were statistically signiﬁcant. Neovascularisation is
a crucial step in the wound healing process.23,24 Angiogenesis is the
growth of new vessels to meet the demand for O2, nutrition and
inﬂammatory cell for wound healing.25 Several angiogenic activa-
tors, including members of the VEGF and FGF gene families and
various inhibitors of angiogenesis, have been described. The
balance between angiogenic activators and inhibitors results in
limited new blood vessel growth in the majority of tissues.26
Animal studies have shown that the administration of VEGF
restores impaired angiogenesis found in diabetic ischemic limbs.10
There are currently only a handful of gene therapy clinical trials
investigating the application of growth factors to chronic wounds.
Margolis27 and colleagues have shown that delivery of a recombi-
nant adenovirus expressing PDGF increased the healing of diabetic
foot ulcers and chronic venous ulcers. Both recombinant and
homologous/autologous growth factors could be used clinically,
where autologous growth factors are harvested from the patients’
own platelets. This approach allows for treatment with patient-
speciﬁc factors in a physiological concentration ratio.3
Our results demonstrate a strong correlation between histo-
logical ﬁndings and bursting pressure. In addition, there is an
important link between collagen deposition and hydroxyproline
level. We found higher hydroxyproline levels and collagen depo-
sition in experimental groups 4 and 5. In group 3, although the
hydroxyproline level was higher than in the control group, collagen
deposition was not found to be signiﬁcantly higher. In conclusion,
this is the ﬁrst study that used growth-factor-mediated gene
therapy for the healing of ischemic colonic anastomosis. This
therapy augmented the levels of hydroxyproline and bursting
pressure. Moreover, this method signiﬁcantly accelerated many of
the histological parameters of ischemic colonic anastomosis.
Combinations of growth factors may have a synergistic effect on
ischemic wound healing processes. Growth-factor-mediated naked
DNA therapy can be effectively used in increasing ischemic wound
healing anastomosis.
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